Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, Dec. 3, 2025 /PRNewswire/ — Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Rxilient Medical Pte. Ltd. (“Rxilient”), for exclusive rights to the commercialization of clobetasol…

Synergy ECP Acquires Federal IT Solutions Leader NetServices

COLUMBIA, Md., Dec. 3, 2025 /PRNewswire/ — Synergy ECP, a provider of software engineering, cybersecurity, and systems engineering services for the U.S. Intelligence and Defense communities, today announced its acquisition of NetServices, a premier provider of secure, innovative…